{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Nonsmall+Cell+Lung+Cancer&page=33",
    "query": {
      "condition": "Advanced Nonsmall Cell Lung Cancer",
      "page": 33
    },
    "page_size": 10
  },
  "pagination": {
    "page": 33,
    "page_size": 10,
    "total_count": 1770,
    "total_pages": 177,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Nonsmall+Cell+Lung+Cancer&page=34&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Nonsmall+Cell+Lung+Cancer&page=32&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T08:42:36.362Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02981108",
      "title": "A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Nonsmall Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "HS-10296",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jiangsu Hansoh Pharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 364,
      "start_date": "2017-05-08",
      "completion_date": "2023-03-31",
      "has_results": true,
      "last_update_posted_date": "2023-01-23",
      "last_synced_at": "2026-11-19T08:42:36.362Z",
      "location_count": 10,
      "location_summary": "Anaheim, California • Beverly Hills, California • San Diego, California + 7 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02981108"
    },
    {
      "nct_id": "NCT03993873",
      "title": "Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Solid Tumors",
        "MET Gene Alterations"
      ],
      "interventions": [
        {
          "name": "elzovantinib (TPX-0022)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Turning Point Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2019-09-05",
      "completion_date": "2027-03-03",
      "has_results": false,
      "last_update_posted_date": "2025-10-01",
      "last_synced_at": "2026-11-19T08:42:36.362Z",
      "location_count": 12,
      "location_summary": "La Jolla, California • Orange, California • Denver, Colorado + 8 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03993873"
    },
    {
      "nct_id": "NCT04033354",
      "title": "A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Squamous Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "HLX10",
          "type": "DRUG"
        },
        {
          "name": "carboplatin and nab paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanghai Henlius Biotech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 537,
      "start_date": "2019-08-14",
      "completion_date": "2023-12-30",
      "has_results": false,
      "last_update_posted_date": "2023-08-08",
      "last_synced_at": "2026-11-19T08:42:36.362Z",
      "location_count": 1,
      "location_summary": "Roanoke, Virginia",
      "locations": [
        {
          "city": "Roanoke",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04033354"
    },
    {
      "nct_id": "NCT06616766",
      "title": "A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "NSCLC (Non-small Cell Lung Cancer)",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "YH42946",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yuhan Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 201,
      "start_date": "2024-10-02",
      "completion_date": "2028-07-29",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-11-19T08:42:36.362Z",
      "location_count": 1,
      "location_summary": "Fairfax, Virginia",
      "locations": [
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06616766"
    },
    {
      "nct_id": "NCT04579380",
      "title": "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Uterine Neoplasms",
        "Uterine Cervical Neoplasms",
        "Biliary Tract Neoplasms",
        "Urologic Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "HER2 Mutations Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "tucatinib",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 217,
      "start_date": "2021-01-11",
      "completion_date": "2026-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-11-19T08:42:36.362Z",
      "location_count": 76,
      "location_summary": "Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04579380"
    },
    {
      "nct_id": "NCT02454842",
      "title": "Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "NSCLC",
        "Non-squamous NSCLC"
      ],
      "interventions": [
        {
          "name": "TH-4000 (Tarloxotinib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rain Oncology Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2015-06",
      "completion_date": "2017-01-31",
      "has_results": false,
      "last_update_posted_date": "2023-01-12",
      "last_synced_at": "2026-11-19T08:42:36.362Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Santa Rosa, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02454842"
    },
    {
      "nct_id": "NCT00004924",
      "title": "Paclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "1999-03",
      "completion_date": "2006-02",
      "has_results": false,
      "last_update_posted_date": "2009-08-25",
      "last_synced_at": "2026-11-19T08:42:36.362Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut • Torrington, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Torrington",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004924"
    },
    {
      "nct_id": "NCT04895579",
      "title": "Lung Cancer With Copanlisib and Durvalumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Copanlisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zhonglin Hao",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2021-05-12",
      "completion_date": "2025-11-12",
      "has_results": false,
      "last_update_posted_date": "2025-11-18",
      "last_synced_at": "2026-11-19T08:42:36.362Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04895579"
    },
    {
      "nct_id": "NCT03265080",
      "title": "A Study of ADXS-NEO Expressing Personalized Tumor Antigens",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colon Cancer Metastatic",
        "Head and Neck Cancer Metastatic",
        "Metastatic Non-Small Cell Lung Cancer",
        "Urothelial Carcinoma",
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "ADXS-NEO",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Advaxis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2018-03-28",
      "completion_date": "2020-11-12",
      "has_results": false,
      "last_update_posted_date": "2023-02-24",
      "last_synced_at": "2026-11-19T08:42:36.362Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • New Orleans, Louisiana + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03265080"
    },
    {
      "nct_id": "NCT02071862",
      "title": "Study of the Glutaminase Inhibitor CB-839 in Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Triple-Negative Breast Cancer",
        "Non Small Cell Lung Cancer",
        "Renal Cell Carcinoma",
        "Mesothelioma",
        "Fumarate Hydratase (FH)-Deficient Tumors",
        "Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)",
        "Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors",
        "Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations",
        "Tumors Harboring Amplifications in the cMyc Gene"
      ],
      "interventions": [
        {
          "name": "CB-839",
          "type": "DRUG"
        },
        {
          "name": "Pac-CB",
          "type": "DRUG"
        },
        {
          "name": "CBE",
          "type": "DRUG"
        },
        {
          "name": "CB-Erl",
          "type": "DRUG"
        },
        {
          "name": "CBD",
          "type": "DRUG"
        },
        {
          "name": "CB-Cabo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calithera Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 210,
      "start_date": "2014-02",
      "completion_date": "2019-03",
      "has_results": false,
      "last_update_posted_date": "2022-07-20",
      "last_synced_at": "2026-11-19T08:42:36.362Z",
      "location_count": 13,
      "location_summary": "San Francisco, California • Stanford, California • Sarasota, Florida + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02071862"
    }
  ]
}